this treatment initially developed by steven rosenberg and colleagues is based on both the transfusion of autologous lymphocytes preactivated in vitro using interleukin 2 and the simultaneous infusion of the lymphokine in vivo .
C0024264
lymphocytes
C0024297
lymphokine